Analyst firms · J.P. Morgan · AVIR
J.P. Morgan AVIR price target and rating history
Atea Pharmaceuticals Inc. (AVIR) · Health Care
J.P. Morgan rates Atea Pharmaceuticals Inc. (AVIR) Underweight with a $8 price target, as of its latest action on Aug 10, 2023. It has published 3 rating actions on AVIR since October 2021, including 0 upgrades and 2 downgrades.
- Current rating
- Underweight
- Price target
- $8
- Median target, all firms
- Too few
- Actions on AVIR
- 3
J.P. Morgan price target on AVIR
Every J.P. Morgan rating on AVIR
- Aug 10, 2023
- Mar 2, 2022
- Oct 20, 2021
Questions about J.P. Morgan and AVIR
- What is J.P. Morgan's price target for AVIR?
- J.P. Morgan's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $8, from its action on Mar 2, 2022.
- What is J.P. Morgan's rating on AVIR?
- J.P. Morgan rates AVIR Underweight, a bearish rating, as of Aug 10, 2023.
- When did J.P. Morgan last change its view on AVIR?
- On Aug 10, 2023, J.P. Morgan downgrades to Underweight from Neutral.
More AVIR rating histories
All J.P. Morgan ratingsAVIR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.